



(11) **EP 2 954 068 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:  
**C12Q 1/68 (2018.01)**

(86) International application number:  
**PCT/IB2014/058790**

(48) Corrigendum issued on:  
**31.10.2018 Bulletin 2018/44**

(87) International publication number:  
**WO 2014/122582 (14.08.2014 Gazette 2014/33)**

(45) Date of publication and mention  
of the grant of the patent:  
**05.09.2018 Bulletin 2018/36**

(21) Application number: **14706699.7**

(22) Date of filing: **04.02.2014**

(54) **DRUG SELECTION FOR NON-SMALL CELL LUNG CANCER THERAPY**

WIRKSTOFFAUSWAHL FÜR EINE THERAPIE GEGEN NICHT-KLEINZELLIGEN LUNGENKREBS

SÉLECTION D'UN MÉDICAMENT POUR UNE THÉRAPIE ANTICANCÉREUSE DU CANCER DU  
POUMON NON À PETITES CELLULES

(84) Designated Contracting States:  
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB**  
**GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO**  
**PL PT RO RS SE SI SK SM TR**

(74) Representative: **J A Kemp**  
**14 South Square**  
**Gray's Inn**  
**London WC1R 5JJ (GB)**

(30) Priority: **05.02.2013 US 201361761105 P**

(56) References cited:  
**WO-A1-2011/008990 WO-A1-2012/088337**  
**WO-A2-2012/119113**

(43) Date of publication of application:  
**16.12.2015 Bulletin 2015/51**

(73) Proprietor: **Pierian Holdings, Inc.**  
**Franklin, TN 37067 (US)**

(72) Inventors:  
• **SINGH, Sharat**  
**Rancho Santa Fe**  
**California 92127 (US)**  
• **KIM, Phillip**  
**Irvine**  
**California 92612 (US)**  
• **LOCKTON, Steven**  
**San Diego**  
**California 92121 (US)**

- **N HOE ET AL: "Selection of targeted agent(s)  
based on matching differential protein  
expression and mutational profile in NSCLC  
patients.", JOURNAL OF CLINICAL ONCOLOGY,**  
**vol. 29, no. 15\_suppl, 20 May 2011 (2011-05-20),**  
**page e21085, XP055020717,**
- **HUA C. GONG ET AL: "Signatures of Drug  
Sensitivity in Nonsmall Cell Lung Cancer",**  
**INTERNATIONAL JOURNAL OF PROTEOMICS,**  
**vol. 2011, 1 January 2011 (2011-01-01), pages**  
**1-13, XP055030274, ISSN: 2090-2166, DOI:**  
**10.1155/2011/215496**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 954 068 B8**